Kancera has dosed the first patient in the combined Phase Ib/IIa KANDOVA study of KAND567 to treat ovarian cancer.

The study intends to enrol a total of 30 ovarian cancer patients with relapse from carboplatin.

Evaluating the tolerability and safety of KAND567 along with carboplatin is the primary objective of the clinical trial.

The secondary objective includes assessing the treatment efficacy of KAND567. Restoring sensitivity to platinum treatment that inhibits tumour growth and prolongs survival is the long-term objective.

The study will be conducted at several university hospitals in Norway, Denmark, and Sweden.

Two sites have already started patient screening with additional two sites anticipated to be initiated in August.

KANDOVA is conducted in partnership with the Nordic Society of Gynaecological Oncology’s clinical trials unit.

Top-line results from the study are expected in the second half of next year.

Kancera CEO Thomas Olin said: “The KANDOVA study is our first clinical study in cancer and having dosed the first patient is a very important milestone for Kancera.”

Said to be the most advanced fractalkine-blocking drug candidate, KAND567 is also being evaluated in the FRACTAL Phase IIa study in myocardial infarction.

Fractalkine is a natural master regulator that controls cancer and immune cells.

The company mainly focuses on the development of drug candidates based on the Fractalkine system.